Page last updated: 2024-11-12
fr 900848
Description
FR 900848: from Streptovericillium fervens; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
jawsamycin : A polyketide that is 5'-amino-5'-deoxy-3,4,5,6-tetrahydrouridine in which one of the hydrogens of the amino group is substituted by a (1E,3E)-1-[(1R,1'R,1''R,1'''R,2S,2'R,2''R,2'''S)-2'''-{(E)-2-[(1R,2R)-2-methylcyclopropyl]ethenyl}[1,1':2',1'':2'',1'''-quater(cyclopropan)]-2-yl]-5-oxopenta-1,3-dien-5-yl group. It is a metabolite isolated from the bacterium, Streptoverticillium fervens and targets the catalytic subunit of the fungal UDP-glycosyltransferase, the first step in the biosynthesis of glycosylphosphatidylinositol (GPI) anchors. It exhibits broad spectrum antifungal activity against several pathogenic fungi including Mucorales. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (10)
Synonym |
fr 900848 |
jawsamycin |
fr900848 |
CHEBI:156382 |
5'-deoxy-5'-({(2e,4e)-5-[(1r,1'r,1''r,1'''r,2s,2'r,2''r,2'''s)-2'''-{(e)-2-[(1r,2r)-2-methylcyclopropyl]ethenyl}[1,1':2',1'':2'',1'''-quater(cyclopropan)]-2-yl]penta-2,4-dienoyl}amino)-5,6-dihydrouridine |
120500-69-8 |
(2e,4e)-n-[[(2r,3s,4r,5r)-5-(2,4-dioxo-1,3-diazinan-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl]-5-[(1s,2r)-2-[(1r,2r)-2-[(1r,2r)-2-[(1r,2s)-2-[(e)-2-[(1r,2r)-2-methylcyclopropyl]ethenyl]cyclopropyl]cyclopropyl]cyclopropyl]cyclopropyl]penta-2,4-dienamide |
uridine, 5'-deoxy-5,6-dihydro-5'-[[(2e,4e)-5-[(1r,1'r,1''r,1'''r,2s,2'r,2''r,2'''s)-2'''-[(1e)-2-[(1r,2r)-2-methylcyclopropyl]ethenyl][1,1':2',1'':2'',1'''-quatercyclopropan]-2-yl]-1-oxo-2,4-pentadien-1-yl]amino]- |
5'-deoxy-5,6-dihydro-5'-[[(2e,4e)-5-[(1r,1'r,1''r,1'''r,2s,2'r,2''r,2'''s)-2'''-[(1e)-2-[(1r,2r)-2-methylcyclopropyl]ethenyl][1,1':2',1'':2'',1'''-quatercyclopropan]-2-yl]-1-oxo-2,4-pentadien-1-yl]amino]uridine |
DTXSID401098276 |
Roles (2)
Role | Description |
bacterial metabolite | Any prokaryotic metabolite produced during a metabolic reaction in bacteria. |
antifungal agent | An antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (5)
Class | Description |
secondary carboxamide | A carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1). |
cyclopropanes | Cyclopropane and its derivatives formed by substitution. |
olefinic compound | Any organic molecular entity that contains at least one C=C bond. |
nucleoside analogue | An analogue of a nucleoside, being an N-glycosyl compound in which the nitrogen-containing moiety is a modified nucleotide base. They are commonly used as antiviral products to prevent viral replication in infected cells. |
polyketide | Natural and synthetic compounds containing alternating carbonyl and methylene groups ('beta-polyketones'), biogenetically derived from repeated condensation of acetyl coenzyme A (via malonyl coenzyme A), and usually the compounds derived from them by further condensations, etc. Considered by many to be synonymous with the less frequently used terms acetogenins and ketides. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (11.11) | 18.2507 |
2000's | 4 (44.44) | 29.6817 |
2010's | 2 (22.22) | 24.3611 |
2020's | 2 (22.22) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 17.54
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 17.54 (24.57) | Research Supply Index | 2.30 (2.92) | Research Growth Index | 4.66 (4.65) | Search Engine Demand Index | 10.37 (26.88) | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 3 (33.33%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (66.67%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |